Hyder Said
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyder Said has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anubhab Nandy
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children’s Hospital and Harvard Medical School , Boston, MA 02115
1 shared publication- Brooke A. Duarte
Department of Psychiatry & Center for Digestive Health, Section of Gastroenterology & Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, USA
1 shared publication - Elizabeth Webb Lampe
Department of Psychological and Brain Sciences Drexel University Philadelphia Pennsylvania USA
1 shared publication - Elyse R. Thakur
Atrium Health Charlotte North Carolina USA
1 shared publication - Jamie Horrigan
Center for Digestive Health, Section of Gastroenterology & Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, USA
1 shared publication - Jean-Frederic Colombel
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication
Latest Publications
- 10 November 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Epstein–Barr virus and inflammatory bowel disease: a systematic review of its clinical significance and potential pathogenic role
Background: Several studies report an association between Epstein–Barr virus (EBV) and inflammatory bowel disease (IBD). This review critically synthesizes current evidence on these association between EBV and IBD, its potential mechanisms, clinical implications, and research gaps. Methods: A systematic search identified studies investigating EBV in IBD using serological, molecular, and tissue-based approaches. Data on EBV prevalence, viral load, disease phenotype, treatment status, and clinical outcomes were extracted, and study quality was assessed. A narrative review examined proposed mechanisms that may potentially link EBV to intestinal inflammation. Results: From 7271 citations, 45 studies met inclusion criteria. EBV was more frequently detected in intestinal tissue from IBD patients than in controls, particularly in active or refractory disease, whereas findings for seroprevalence and blood-based markers were less consistent. Some longitudinal studies reported associations between prior EBV exposure and subsequent IBD, particularly Crohn’s disease, but these observations do not establish a causal relationship. Proposed mechanisms involving EBV-infected B cells, molecular mimicry, and altered cytokine signaling provide biological plausibility but remain unproven in IBD. EBV latency programs and age at seroconversion may influence disease progression and reactivation risk, although data remain limited. Corticosteroids and therapy with infliximab plus azathioprine have been associated with higher EBV loads, especially in refractory disease, yet these findings may be confounded by disease severity and treatment exposure. Conclusions: Current evidence supports an association between EBV and IBD, particularly in severe and refractory disease but does not establish—and equally does not exclude—a pathogenic role for EBV. Considerable methodological heterogeneity in study design and EBV detection methods and the observational nature of the available data limit causal interpretation. Prospective mechanistic studies are needed to determine whether EBV is a causal contributor, a disease modifier, or a marker of underlying immune dysregulation.
- 10 November 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Epstein–Barr virus and inflammatory bowel disease: a systematic review of its clinical significance and potential pathogenic role
Background: Several studies report an association between Epstein–Barr virus (EBV) and inflammatory bowel disease (IBD). This review critically synthesizes current evidence on these association between EBV and IBD, its potential mechanisms, clinical implications, and research gaps. Methods: A systematic search identified studies investigating EBV in IBD using serological, molecular, and tissue-based approaches. Data on EBV prevalence, viral load, disease phenotype, treatment status, and clinical outcomes were extracted, and study quality was assessed. A narrative review examined proposed mechanisms that may potentially link EBV to intestinal inflammation. Results: From 7271 citations, 45 studies met inclusion criteria. EBV was more frequently detected in intestinal tissue from IBD patients than in controls, particularly in active or refractory disease, whereas findings for seroprevalence and blood-based markers were less consistent. Some longitudinal studies reported associations between prior EBV exposure and subsequent IBD, particularly Crohn’s disease, but these observations do not establish a causal relationship. Proposed mechanisms involving EBV-infected B cells, molecular mimicry, and altered cytokine signaling provide biological plausibility but remain unproven in IBD. EBV latency programs and age at seroconversion may influence disease progression and reactivation risk, although data remain limited. Corticosteroids and therapy with infliximab plus azathioprine have been associated with higher EBV loads, especially in refractory disease, yet these findings may be confounded by disease severity and treatment exposure. Conclusions: Current evidence supports an association between EBV and IBD, particularly in severe and refractory disease but does not establish—and equally does not exclude—a pathogenic role for EBV. Considerable methodological heterogeneity in study design and EBV detection methods and the observational nature of the available data limit causal interpretation. Prospective mechanistic studies are needed to determine whether EBV is a causal contributor, a disease modifier, or a marker of underlying immune dysregulation.
- 31 October 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Sleep disturbance in inflammatory bowel disease: clinical associations and gaps in care
Background and aims: Sleep disturbance is highly prevalent in inflammatory bowel disease (IBD), affecting up to 70% of patients with active disease and 40% in remission, and is associated with worse clinical and patient-reported outcomes. Understanding of the multifactorial drivers of sleep disturbances in IBD remains limited, and as such, there is an absence of clear guidance for evaluating and managing sleep problems in this population. We aimed to identify factors associated with sleep disturbance and characterize patient beliefs, self-management strategies, and interest in sleep-focused testing and treatments. Methods: Adults with Crohn disease and ulcerative colitis completed a cross-sectional survey assessing disease activity, sleep quality, stress, chronotype, fatigue, and mood. A study-specific questionnaire evaluated sleep-related beliefs, behaviors, and treatment interest. Descriptive analyses characterized sleep patterns and behaviors, and multivariable regression identified factors associated with poor sleep. Results: Among 204 participants, 76.5% reported poor sleep quality and 55.9% had clinically significant sleep disturbance, which was more common in active disease than remission (80.9% vs 46.0%, P < .001). Active disease (odds ratio [OR], 4.31), higher perceived stress (OR, 1.21), and anxiety (OR, 2.63) were associated with increased odds of clinically significant sleep disturbance, while intermediate (OR, 0.16) and morning chronotypes (OR, 0.07) were associated with lower odds of clinically significant sleep disturbance compared with evening chronotypes. Most participants reported self-management behaviors related to sleep, with widespread use of sleep hygiene and over-the-counter strategies but minimal exposure to cognitive behavioral therapy for insomnia (0.5%). Interest in sleep-focused interventions was high, particularly for wearable monitoring, home-based testing, and behavioral and light-based therapies. Conclusion: Sleep disturbance in inflammatory bowel disease is common and reflects interacting inflammatory, psychological, and circadian factors. Use of evidence-based therapies remains extremely limited, highlighting a substantial gap in care.
- 31 October 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Sleep disturbance in inflammatory bowel disease: clinical associations and gaps in care
Background and aims: Sleep disturbance is highly prevalent in inflammatory bowel disease (IBD), affecting up to 70% of patients with active disease and 40% in remission, and is associated with worse clinical and patient-reported outcomes. Understanding of the multifactorial drivers of sleep disturbances in IBD remains limited, and as such, there is an absence of clear guidance for evaluating and managing sleep problems in this population. We aimed to identify factors associated with sleep disturbance and characterize patient beliefs, self-management strategies, and interest in sleep-focused testing and treatments. Methods: Adults with Crohn disease and ulcerative colitis completed a cross-sectional survey assessing disease activity, sleep quality, stress, chronotype, fatigue, and mood. A study-specific questionnaire evaluated sleep-related beliefs, behaviors, and treatment interest. Descriptive analyses characterized sleep patterns and behaviors, and multivariable regression identified factors associated with poor sleep. Results: Among 204 participants, 76.5% reported poor sleep quality and 55.9% had clinically significant sleep disturbance, which was more common in active disease than remission (80.9% vs 46.0%, P < .001). Active disease (odds ratio [OR], 4.31), higher perceived stress (OR, 1.21), and anxiety (OR, 2.63) were associated with increased odds of clinically significant sleep disturbance, while intermediate (OR, 0.16) and morning chronotypes (OR, 0.07) were associated with lower odds of clinically significant sleep disturbance compared with evening chronotypes. Most participants reported self-management behaviors related to sleep, with widespread use of sleep hygiene and over-the-counter strategies but minimal exposure to cognitive behavioral therapy for insomnia (0.5%). Interest in sleep-focused interventions was high, particularly for wearable monitoring, home-based testing, and behavioral and light-based therapies. Conclusion: Sleep disturbance in inflammatory bowel disease is common and reflects interacting inflammatory, psychological, and circadian factors. Use of evidence-based therapies remains extremely limited, highlighting a substantial gap in care.
- Open Access
- 16 December 2025
- Published by Springer Nature in Current Sleep Medicine Reports
- Vol. 11 (1) , 37
Mind-Body Interventions for Comorbid Sleep and Gastrointestinal Concerns
Purpose of Review Sleep disturbances are common in individuals with gastrointestinal (GI) disorders. The connection between sleep and GI symptoms is bidirectional and influenced by shared biopsychosocial mechanisms and cognitive-behavioral factors, including alterations in the stress response. Treating sleep disturbances can effectively manage coexisting symptoms. This review explores current research on sleep treatments for GI conditions, emphasizing mind-body interventions that target stress. Recent Findings Both pharmacological and non-pharmacological approaches (e.g., cognitive behavioral therapy for insomnia) benefit patients with sleep disturbance and concomitant GI symptoms; however, they have limitations. Other approaches, including mind-body interventions, may improve sleep quality, reduce GI symptoms, and enhance quality of life. Summary Mind-body interventions can complement other evidence-based approaches for patients with co-morbid sleep disturbance and GI symptoms. However, more rigorous research is warranted to fully understand their benefit. As research evolves, healthcare professionals can guide patients on how to best integrate these approaches into their care.
- 16 December 2025
- Published by Springer Nature in Current Sleep Medicine Reports
- Vol. 11 (1) , 37
Open AccessMind-Body Interventions for Comorbid Sleep and Gastrointestinal Concerns
Purpose of Review Sleep disturbances are common in individuals with gastrointestinal (GI) disorders. The connection between sleep and GI symptoms is bidirectional and influenced by shared biopsychosocial mechanisms and cognitive-behavioral factors, including alterations in the stress response. Treating sleep disturbances can effectively manage coexisting symptoms. This review explores current research on sleep treatments for GI conditions, emphasizing mind-body interventions that target stress. Recent Findings Both pharmacological and non-pharmacological approaches (e.g., cognitive behavioral therapy for insomnia) benefit patients with sleep disturbance and concomitant GI symptoms; however, they have limitations. Other approaches, including mind-body interventions, may improve sleep quality, reduce GI symptoms, and enhance quality of life. Summary Mind-body interventions can complement other evidence-based approaches for patients with co-morbid sleep disturbance and GI symptoms. However, more rigorous research is warranted to fully understand their benefit. As research evolves, healthcare professionals can guide patients on how to best integrate these approaches into their care.